| Literature DB >> 32968397 |
Chandrika Dasgupta1, Md Abdur Rafi2, Md Abdus Salam3.
Abstract
OBJECTIVES: Urinary tract infections due to multi drug resistant bacteria have been on the rise globally with serious implications for public health. The objective of this study was to explore the prevalence of multi drug resistant uropathogens and to correlate the urinary tract infections with some demographic and clinical characteristics of patients admitted in a tertiary care hospital in Bangladesh.Entities:
Keywords: Antibiogram; Bangladesh; Multidrug resistant uropathogens; Tertiary care hospital
Year: 2020 PMID: 32968397 PMCID: PMC7501044 DOI: 10.12669/pjms.36.6.2943
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 1.088
Frequency of culture-positive (n = 537) and MDR (n = 420) uropathogens.
| Uropathogens | Frequency of culture-positive isolates n (%) | Frequency of MDR isolates n (%) |
|---|---|---|
| Escherichia coli | 331 (61.6) | 257 (77.6) |
| Klebsiella spp. | 121 (22.5) | 87 (71.9) |
| Pseudomonas spp. | 42 (7.8) | 38 (90.5) |
| Staphylococcus aureus | 29 (5.4) | 25 (86.2) |
| Enterobacter spp. | 14 (2.6) | 13 (92.9) |
| Total | 537 (100) | 420 (78.2) |
Correlation of UTI with demographic and clinical characteristics of the patients.
| Characteristics | Culture-positive n(%) | Culture-negative n(%) | Total n(%) | P-value |
|---|---|---|---|---|
| Female | 356 (66.3) | 422 (58.8) | 778 (62.0) | 0.007 |
| Male | 181 (33.7) | 296 (41.2) | 477 (38.0) | |
| < 5 years | 70 (13.0) | 92 (12.8) | 162 (12.9) | 0.994 |
| 5 – 18 years | 40 (7.4) | 50 (7.0) | 90 (7.2) | |
| 19 – 30 years | 95 (17.7) | 135 (18.8) | 230 (18.3) | |
| 31 – 40 years | 65 (12.1) | 92 (12.8) | 157 (12.5) | |
| 41 – 50 years | 71 (13.2) | 98 (13.6) | 169 (13.5) | |
| 51 – 60 years | 83 (15.5) | 104 (14.5) | 187 (14.9) | |
| > 60 years | 113 (21.0) | 147 (20.5) | 260 (20.7) | |
| Hypertension | 108 (20.1) | 140 (19.5) | 248 (19.8) | 0.487 |
| Diabetes mellitus | 139 (25.8) | 92 (12.8) | 231 (18.4) | 0.004 |
| Ischaemic heart disease | 20 (3.7) | 32 (4.4) | 52 (4.1) | 0.364 |
| Chronic obstructive pulmonary disease | 21 (3.9) | 28 (3.8) | 49 (3.9) | 0.148 |
| Chronic renal failure | 23 (4.2) | 16 (2.2) | 39 (3.1) | 0.029 |
| Asthma | 11 (2.1) | 17 (2.3) | 28 (2.2) | 0.774 |
| Dysuria | 432 (80.5) | 559 (77.8) | 991 (79.0) | 0.372 |
| Frequency | 296 (55.1) | 375 (52.2) | 671 (53.5) | 0.143 |
| Fever | 257 (47.8) | 166 (23.2) | 423 (33.7) | 0.012 |
| Urgency | 192 (35.7) | 206 (28.7) | 398 (31.7) | 0.271 |
| Supra-pubic pain | 158 (29.4) | 174 (24.2) | 332 (26.5) | 0.048 |
| Nocturia | 84 (15.6) | 98 (13.6) | 182 (14.5) | 0.153 |
| Haematuria | 30 (5.6) | 32 (4.4) | 62 (4.9) | 0.076 |
Frequency of antimicrobial resistance of uropathogens (n = 537).
| Antimicrobial Agents | Escherichia coli (n = 331) | Klebsiella spp. (n = 121) | Pseudomonas spp. (n = 42) | Staphylococcus aureus (n = 29) | Enterobacter spp. (n = 14) | Total MDR n (%) |
|---|---|---|---|---|---|---|
| Cefixime | 187 (56.5) | 74 (61.2) | 25 (59.5) | 12 (41.4) | 11 (78.6) | 309 (57.5) |
| Ceftriaxone | 166 (50.2) | 69 (57.0) | 16 (38.1) | 3 (10.3) | 7 (50.0) | 261 (48.6) |
| Ceftazidime | 128 (38.7) | 53 (43.8) | 12 (28.6) | 9 (31.0) | 10 (71.4) | 212 (39.5) |
| Cefepime | 158 (47.7) | 57 (47.1) | 13 (31.0) | 10 (34.5) | 10 (71.4) | 248 (46.2) |
| Amikacin | 29 (8.8) | 16 (13.2) | 2 (4.8) | 2 (6.9) | 3 (21.4) | 52 (9.7) |
| Gentamicin | 134 (40.5) | 55 (45.5) | 22 (52.4) | 13 (44.8) | 9 (64.3) | 233 (43.4) |
| Imipenem | 9 (2.7) | 5 (4.1) | 1 (2.4) | 1 (3.4) | 4 (28.6) | 20 (3.7) |
| Meropenem | 8 (2.4) | 9 (7.4) | 2 (4.8) | 2 (6.9) | 6 (42.9) | 27 (5.0) |
| Ciprofloxacin | 189 (57.1) | 46 (38.0) | 14 (33.3) | 18 (62.1) | 10 (71.4) | 277 (51.6) |
| Levofloxacin | 173 (52.3) | 41 (33.9) | 12 (28.6) | 4 (13.8) | 10 (71.4) | 240 (44.7) |
| Azithromycin | 178 (53.8) | 66 (54.5) | 20 (47.6) | 18 (62.1) | 9 (64.3) | 291 (54.2) |
| Cefuroxime | 154 (46.5) | 70 (57.9) | 26 (61.9) | 18 (62.1) | 9 (64.3) | 277 (51.6) |
| Aztreonam | 131 (39.6) | 61 (50.4) | 12 (28.6) | 24 (82.8) | 13 (92.9) | 241 (44.9) |
| Cotrimoxazole | 192 (58.0) | 66 (54.5) | 35 (83.3) | 20 (69.0) | 8 (57.1) | 321 (59.8) |
| Nitrofurantoin | 68 (20.5) | 39 (32.2) | 28 (66.7) | 5 (17.2) | 3 (21.4) | 143 (26.6) |
| Netilmicin | 60 (18.1) | 38 (31.4) | 10 (23.8) | 8 (27.6) | 3 (21.4) | 119 (22.2) |
| Nalidixic Acid | 292 (88.2) | 110 (90.9) | 35 (83.3) | 24 (82.8) | 12 (85.7) | 473 (88.1) |
N.B. Figures in the parentheses indicate percentage.